S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
Log in
NASDAQ:ORGO

Organogenesis Stock Forecast, Price & News

$15.21
+0.70 (+4.82 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.19
Now: $15.21
$15.99
50-Day Range
$7.34
MA: $11.27
$14.59
52-Week Range
$2.47
Now: $15.21
$16.50
Volume793,572 shs
Average Volume918,399 shs
Market Capitalization$1.64 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.84
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ORGO
CUSIPN/A
CIKN/A
Phone781-575-0775
Employees835
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$260.98 million
Book Value$0.59 per share

Profitability

Net Income$-40,450,000.00

Miscellaneous

Market Cap$1.64 billion
Next Earnings Date3/16/2021 (Confirmed)
OptionableNot Optionable

MarketRank

Overall MarketRank

0.99 out of 5 stars

Medical Sector

1029th out of 1,960 stocks

Pharmaceutical Preparations Industry

478th out of 771 stocks

Analyst Opinion: 1.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$15.21
+0.70 (+4.82 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ORGO News and Ratings via Email

Sign-up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Organogenesis (NASDAQ:ORGO) Frequently Asked Questions

Is Organogenesis a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Organogenesis in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Organogenesis stock.
View analyst ratings for Organogenesis
or view top-rated stocks.

What stocks does MarketBeat like better than Organogenesis?

Wall Street analysts have given Organogenesis a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Organogenesis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Organogenesis' next earnings date?

Organogenesis is scheduled to release its next quarterly earnings announcement on Tuesday, March 16th 2021.
View our earnings forecast for Organogenesis
.

How can I listen to Organogenesis' earnings call?

Organogenesis will be holding an earnings conference call on Tuesday, March 16th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Organogenesis' earnings last quarter?

Organogenesis Holdings Inc. (NASDAQ:ORGO) announced its quarterly earnings results on Monday, November, 9th. The company reported $0.19 earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.08) by $0.27. The business had revenue of $100.80 million for the quarter, compared to the consensus estimate of $99.50 million. Organogenesis had a negative trailing twelve-month return on equity of 10.03% and a negative net margin of 1.61%.
View Organogenesis' earnings history
.

How has Organogenesis' stock price been impacted by COVID-19?

Organogenesis' stock was trading at $2.98 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ORGO stock has increased by 410.4% and is now trading at $15.21.
View which stocks have been most impacted by COVID-19
.

What guidance has Organogenesis issued on next quarter's earnings?

Organogenesis issued an update on its fourth quarter earnings guidance on Wednesday, January, 13th. The company provided earnings per share (EPS) guidance of positive EPS for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.01. The company issued revenue guidance of $104.6-106.0 million, compared to the consensus revenue estimate of $80.84 million.

What price target have analysts set for ORGO?

4 brokerages have issued 12-month target prices for Organogenesis' shares. Their forecasts range from $9.00 to $14.00. On average, they expect Organogenesis' share price to reach $11.25 in the next year. This suggests that the stock has a possible downside of 26.0%.
View analysts' price targets for Organogenesis
or view top-rated stocks among Wall Street analysts.

Who are Organogenesis' key executives?

Organogenesis' management team includes the following people:
  • Mr. Gary S. Gillheeney Sr., Pres, CEO & Director (Age 66, Pay $1.44M)
  • Ms. Lori H. Freedman, VP & Gen. Counsel (Age 54, Pay $508.71k)
  • Mr. Brian Grow, Chief Commercial Officer (Age 45, Pay $605.8k)
  • Mr. David C. Francisco, Chief Financial Officer
  • Mr. Patrick Bilbo, Chief Operating Officer (Age 60)
  • Mr. Thomas L. Pearl, VP of HR
  • Dr. Zorina Pitkin, Sr. VP of Quality Systems
  • Mr. Henry Hagopian III, Sr. VP of Fin. & Treasurer (Age 53)
  • Mr. William R. Kolb CPA, Sec.

Who are some of Organogenesis' key competitors?

What other stocks do shareholders of Organogenesis own?

What is Organogenesis' stock symbol?

Organogenesis trades on the NASDAQ under the ticker symbol "ORGO."

Who are Organogenesis' major shareholders?

Organogenesis' stock is owned by a number of retail and institutional investors. Top institutional investors include Avidity Partners Management LP (5.12%), Emerald Mutual Fund Advisers Trust (1.71%), Pura Vida Investments LLC (1.68%), BlackRock Inc. (1.17%), Renaissance Technologies LLC (0.60%) and Laurion Capital Management LP (0.52%). Company insiders that own Organogenesis stock include Alan A Ades, Arthur S Leibowitz, Avista Capital Managing Member, Gary S Gillheeney, Glenn H Nussdorf, Michael W Katz and Wayne D Mackie.
View institutional ownership trends for Organogenesis
.

Which major investors are selling Organogenesis stock?

ORGO stock was sold by a variety of institutional investors in the last quarter, including State of Wisconsin Investment Board, and Barclays PLC. Company insiders that have sold Organogenesis company stock in the last year include Gary S Gillheeney, and Glenn H Nussdorf.
View insider buying and selling activity for Organogenesis
or view top insider-selling stocks.

Which major investors are buying Organogenesis stock?

ORGO stock was bought by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, Emerald Mutual Fund Advisers Trust, Pura Vida Investments LLC, Laurion Capital Management LP, Renaissance Technologies LLC, BlackRock Inc., Charles Schwab Investment Management Inc., and New York Life Investments Alternatives. Company insiders that have bought Organogenesis stock in the last two years include Alan A Ades, Arthur S Leibowitz, Avista Capital Managing Member, Michael W Katz, and Wayne D Mackie.
View insider buying and selling activity for Organogenesis
or or view top insider-buying stocks.

How do I buy shares of Organogenesis?

Shares of ORGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Organogenesis' stock price today?

One share of ORGO stock can currently be purchased for approximately $15.21.

How much money does Organogenesis make?

Organogenesis has a market capitalization of $1.64 billion and generates $260.98 million in revenue each year. The company earns $-40,450,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis.

How many employees does Organogenesis have?

Organogenesis employs 835 workers across the globe.

What is Organogenesis' official website?

The official website for Organogenesis is organogenesis.com.

Where are Organogenesis' headquarters?

Organogenesis is headquartered at 85 Dan Road, Canton MA, 02021.

How can I contact Organogenesis?

Organogenesis' mailing address is 85 Dan Road, Canton MA, 02021. The company can be reached via phone at 781-575-0775 or via email at [email protected]


This page was last updated on 2/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.